TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27734128

Group type: EXPERIMENTAL
Intervention: P 3‐DXAs drink
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3‐DXAs drink
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink (low in 3‐DXAs and without proanthocyanidins)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-sorghum drink
Number of subjects: 10
Study: 26985629

Group type: EXPERIMENTAL
Intervention: OTO‐201 (single‐dose intratympanic, intraoperative, thermosensitive, otic suspension of ciprofloxacin)
Number of subjects: 532

Group type: COMPARATOR
Intervention: TTP only (control group)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: OTO‐201
Number of subjects: 532
Study: 24297946

Group type: EXPERIMENTAL
Intervention: Optimized high-dose imatinib
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Imatinib 400 mg/day
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Confirmed MR(4.5)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: High-dose imatinib
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Early major molecular remission
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: No patient with confirmed MR(4.5)
Number of subjects: 1524
Study: 21484793

Group type: EXPERIMENTAL
Intervention: Vaginal brush device for hrHPV testing (self-sampling group, n = 26,145)
Number of subjects: 26409

Group type: COMPARATOR
Intervention: Recall for regular cytology-based screening (recall control group, n = 264)
Number of subjects: 26409
Study: 19401825

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 1257
Study: 18405790

Group type: EXPERIMENTAL
Intervention: Sequential regimen: pantoprazole 40 mg and amoxicillin 1 g for 7 days, followed by pantoprazole 40 mg, tetracycline 500 mg, and metronidazole 500 mg for the next 7 days.
Number of subjects: 300

Group type: COMPARATOR
Intervention: PAC group: pantoprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg for 14 days.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nonsmoking patients in sequential group.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smoking patients in sequential group.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nonsmoking patients in PAC group.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smoking patients in PAC group.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall adverse events reported.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sequential group adverse events.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PAC group adverse events.
Number of subjects: 300
Study: 15986288

Group type: EXPERIMENTAL
Intervention: Endoscopic dilatation of dominant stenoses in PSC patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Elevated CA19-9 levels in PSC patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of dominant stenoses
Number of subjects: 106
Study: 12566675

Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10233049

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol.kg-1.min-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 7815178

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (800 micrograms/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zinc intake (3.5 mg/d or 14.5 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2016011

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed to patients with clinical signs and symptoms of pharyngitis.
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Antibiotics effective against Mycoplasma and Chlamydia.
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Projected costs of drug treatment for patients with NSP.
Number of subjects: 358
Study: 7073802

Group type: COMPARATOR
Intervention: Moderate-fat high polyunsaturated fat diet (MOD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LO)
Number of subjects: 35
Study: 30325775

Group type: EXPERIMENTAL
Intervention: HIV-1 infected Arab MSM (AMSM)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: HIV-1 infected Jewish MSM (JMSM)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Overall population of MSM
Number of subjects: 1143
Study: 29888971

Group type: EXPERIMENTAL
Intervention: BladderScan® BVI 6100 ultrasound device
Number of subjects: 190
Study: 27250828

Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy
Number of subjects: 29
Study: 24256483

Group type: EXPERIMENTAL
Intervention: Automated vasopressor system (phenylephrine 50 μg or ephedrine 4 mg)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Manual boluses (phenylephrine 100 μg or ephedrine 8 mg)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Automated vasopressor system
Number of subjects: 213

Group type: COMPARATOR
Intervention: Manual boluses
Number of subjects: 213
Study: 22784862

Group type: EXPERIMENTAL
Intervention: Low BIS anesthesia
Number of subjects: 40
Study: 20035337

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MD) with high intake of virgin olive oil (VOO)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MD) with high intake of nuts
Number of subjects: 737

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 737
Study: 18544145

Group type: EXPERIMENTAL
Intervention: Ketamine (5 mg.kg(‐1) intramuscular)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sevoflurane (3% concentration, increased after every three breaths)
Number of subjects: 47
Study: 16158372

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration training (3 times weekly for 5 weeks, 35-40 Hz, 1.7-2.5 mm, Power Plate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (conventional training only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 12955684

Group type: EXPERIMENTAL
Intervention: SF170E; modified cellulose triacetate/midflux membrane
Number of subjects: 211

Group type: COMPARATOR
Intervention: HF80LS; polysulfone/high‐flux membrane
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 11572225

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (diode 670 nm and Helium‐Neon 632.8 nm) at frequencies of 5 Hz, 292 Hz, and 9,000 Hz
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (nonlaser therapy)
Number of subjects: 150
Study: 9197961

Group type: EXPERIMENTAL
Intervention: Moisturizing cream (test cream)
Number of subjects: 0
Study: 8457531

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (70 mg Zn twice weekly for 1.25 years)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 110
Study: 3537626

Group type: EXPERIMENTAL
Intervention: Stim‐O‐Stam (acute: 1.24 g one hour before exercise)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stim‐O‐Stam (chronic: 3.73 g X d‐1 for 6 d prior to exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 29396713

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib after crossover from IFN
Number of subjects: 0
Study: 26729619

Group type: EXPERIMENTAL
Intervention: High nicotine strength products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium nicotine strength products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zero nicotine strength products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quitters (smoking cessation phenotype)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Failures and Reducers (smoking phenotypes)
Number of subjects: 0
Study: 24889854

Group type: EXPERIMENTAL
Intervention: Pain biology education (2×1 hour sessions)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sham education (2×1 hour sessions)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Pain biology education
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sham education
Number of subjects: 202
Study: 21627741

Group type: EXPERIMENTAL
Intervention: Reflux symptoms (never, monthly or less often, weekly or more often)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: High risk of OSA (23% of participants)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: BMI > 25 (63% of participants, 22% > 30)
Number of subjects: 2700
Study: 20088941

Group type: EXPERIMENTAL
Intervention: Acarbose up to 100 mg three times a day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17438254

Group type: EXPERIMENTAL
Intervention: Vestibular exercises (8 patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo exercises (5 patients)
Number of subjects: 13
Study: 16259869

Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy, TG-43)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Pd-103 (125 Gy, NIST-99)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: I-125
Number of subjects: 352

Group type: COMPARATOR
Intervention: Pd-103
Number of subjects: 352
Study: 12451343

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10403264

Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg/day
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 8772864

Group type: EXPERIMENTAL
Intervention: Partial exchange blood transfusion with normal saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Partial exchange blood transfusion with plasma
Number of subjects: 30
Study: 2119678

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 9
Study: 7204956

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 80
Study: 31765976

Group type: EXPERIMENTAL
Intervention: 400 mgI/kg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 500 mgI/kg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 600 mgI/kg
Number of subjects: 204
Study: 31292311

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 20
Study: 28693594

Group type: EXPERIMENTAL
Intervention: Perioperative infusion regime with sodium glycerophosphate and Jonosteril®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jonosteril® (comparator) alone
Number of subjects: 0
Study: 25294611

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD, inhaled)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BUD/FM, inhaled)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Procaterol tablet (PT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 80
Study: 24848284

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100‐250 mg bid)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 22222146

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 19782476

Group type: EXPERIMENTAL
Intervention: Single nasal testosterone dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17376106

Group type: EXPERIMENTAL
Intervention: Migraine at age 6 years
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Tension-type headache
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Concurrent symptoms with headache
Number of subjects: 1132
Study: 15608429

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11888760

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Warm blood cardioplegia
Number of subjects: 35
Study: 10362952

Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention for breathlessness
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 52
Study: 7605760

Group type: EXPERIMENTAL
Intervention: Plain 'alkalinized' 0.5% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain 'non‐alkalinized' 0.5% bupivacaine
Number of subjects: 30
Study: 2136968

Group type: EXPERIMENTAL
Intervention: Intravenous isradipine (0.01 mg/kg, n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study: 7084649

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 45
Study: 30657013

Group type: EXPERIMENTAL
Intervention: FLEX (torsionally flexible shoe sole)
Number of subjects: 8

Group type: COMPARATOR
Intervention: STIFF (relatively stiffer shoe sole)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 8

Group type: COMPARATOR
Intervention: STIFF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FLEX responders
Number of subjects: 8
Study: 27400891

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound-guided femoral nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous epidural analgesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 25012957

Group type: EXPERIMENTAL
Intervention: Nurse-delivered brief health education intervention (3-min telephone + 3-min face-to-face)
Number of subjects: 2517

Group type: COMPARATOR
Intervention: Standard care (health education leaflets and/or video show)
Number of subjects: 2517
Study: 23901266

Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 58
Study: 21134105

Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1802
Study: 19817721

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 340
Study: 19134041

Group type: EXPERIMENTAL
Intervention: Ethanol rinse before luting with All Bond 2 adhesive system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control application of All Bond 2 adhesive system without ethanol rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol rinse before luting with One Step Plus adhesive system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control application of One Step Plus adhesive system without ethanol rinse
Number of subjects: 0
Study: 16002021

Group type: EXPERIMENTAL
Intervention: Reinforcement-based therapy (RBT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 12468789

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 22
Study: 9395384

Group type: EXPERIMENTAL
Intervention: Daily primaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (unvaccinated control)
Number of subjects: 0
Study: 7966041

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole, 400 mg daily for 14 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Clotrimazole vaginal suppositories, 100 mg daily for 7 days
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 151

Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Systemic ketoconazole
Number of subjects: 151
Study: 3311440

Group type: EXPERIMENTAL
Intervention: Mefloquine plus sulfadoxine-pyrimethamine (Fansimef)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (Fansidar)
Number of subjects: 100
Study: 12418395

Group type: EXPERIMENTAL
Intervention: High doses of beta-interferon used every other day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0
Study: 27884047

Group type: EXPERIMENTAL
Intervention: Active intervention (weight gain prevention)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Attention control (oral health)
Number of subjects: 272
Study: 27703286

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 60
Study: 24948466

Group type: EXPERIMENTAL
Intervention: BCG with or without isoniazid (INH)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 822
Study: 22325844

Group type: EXPERIMENTAL
Intervention: Thrice-weekly intensive phase therapy
Number of subjects: 750

Group type: COMPARATOR
Intervention: Daily intensive phase therapy
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 750

Group type: COMPARATOR
Intervention: Non-HIV-infected participants
Number of subjects: 750
Study: 20375228

Group type: EXPERIMENTAL
Intervention: Read It Again! (RIA) curriculum implemented by teachers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (teachers not implementing RIA)
Number of subjects: 20
Study: 18604321

Group type: EXPERIMENTAL
Intervention: Standard nutritional supplement
Number of subjects: 537

Group type: COMPARATOR
Intervention: Hospital diet according to needs and pathology
Number of subjects: 537
Study: 16002932

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg IV, q12h)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Cefotaxime (1g IV, q8h) + Ofloxacin (200 mg IV, q12h)
Number of subjects: 398
Study: 12442932

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.05 microg kg(‐1) i.v. (Group A, n = 15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clonidine 2 microg kg(‐1) i.v. (Group B, n = 17)
Number of subjects: 32
Study: 10604046

Group type: EXPERIMENTAL
Intervention: Peppermint oil and caraway oil combination preparation (PCC, Enteroplant)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cisapride (CIS, CAS 81098‐60‐4)
Number of subjects: 120
Study: 7791267

Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) daily for 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no EPA‐E)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) for 2 months
Number of subjects: 10
Study: 1942284

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sedimentation rate
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sedimentation rate elevated 20 mm/hour
Number of subjects: 150
Study: 6820891

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 consecutive days before surgery, repeated every fortnight for one year after surgery)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Mitomycin C (20 mg day 0, 10 mg day 1, one shot i.v.) and 5-FU (150 mg/day, p.o.)
Number of subjects: 342
Study: 31030167

Group type: EXPERIMENTAL
Intervention: Walnuts (40 g/day for 4 weeks)
Number of subjects: 15
Study: 28122805

Group type: EXPERIMENTAL
Intervention: Double kissing crush
Number of subjects: 370

Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Complex bifurcation lesions
Number of subjects: 370

Group type: COMPARATOR
Intervention: Provisional stenting in complex bifurcation
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Final kissing balloon inflation
Number of subjects: 370
Study: 27094558

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MET)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24452849

Group type: EXPERIMENTAL
Intervention: sitagliptin 50-100 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: sitagliptin-free period
Number of subjects: 19
Study: 22081052

Group type: EXPERIMENTAL
Intervention: Rikkunshito (7.5 g/day) with a standard dose of RPZ (10 mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Double dose of RPZ (20 mg/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rikkunshito group (specifically male NERD patients)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Rikkunshito group (NERD patients with low BMI)
Number of subjects: 104
Study: 19410209

Group type: EXPERIMENTAL
Intervention: Group prenatal care (CenteringPregnancy model)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 322
Study: 17123673

Group type: EXPERIMENTAL
Intervention: Forearm Bier's block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Bier's block
Number of subjects: 30
Study: 16360449

Group type: EXPERIMENTAL
Intervention: Prostatic massage
Number of subjects: 51
Study: 11465651

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + HCTZ 12.5 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + Benazepril 20 mg/day
Number of subjects: 88
Study: 15010720

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 7917736

Group type: EXPERIMENTAL
Intervention: Atracurium infusion with prior administration of suxamethonium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium infusion without prior administration of suxamethonium
Number of subjects: 20
Study: 3294318

Group type: EXPERIMENTAL
Intervention: Antibiotic/steroid ear drops
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Active therapy (antibiotic/steroid ear drops)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Gentamicin (antibiotic used in active therapy)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 163